Academic Journals Database
Disseminating quality controlled scientific knowledge

Clastogenic effects of the anticancer drug Epirubicin on mouse bone marrow cells

ADD TO MY LIST
 
Author(s): RS Pandit

Journal: Biology and Medicine
ISSN 0974-8369

Volume: 3;
Issue: 5;
Start page: 43;
Date: 2011;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: Epirubicin | Anthracycline antibiotic | Chromosome aberration | Micronucleus | Bone marrow cells | Swiss mice

ABSTRACT
Epirubicin, a semi-synthetic anthracycline antibiotic, is widely prescribed singly or in combination therapy for thetreatment of various types of cancers. However, the reported occurrence of second malignancy in epirubicin pretreatedcancer survivors has necessitated its cytogenotoxicity testing. Therefore, the clastogenic potential ofepirubicin was assessed here from bone marrow cells of Swiss mice after single intraperitoneal administration of thedrug. Each of the three tested doses of epirubicin (2, 4 and 6 mg kg-1 b. w.) induced significantly high percentages (p≤ 0.01) of aberrant metaphases and chromosomal aberrations (excluding gaps) at 24 h post-treatment and significantincrease (p ≤ 0.05) in the frequency of micronucleus in polychromatic erythrocytes at 30 h post-treatment. Thus,epirubicin was highly clastogenic to bone marrow cells of Swiss mice. Its interference in the activity of topoisomerase-II and its free radical generation potential were attributed to its clastogenicity. Such clastogenic effects of epirubicinmight have been the cause of recurrence of second malignancy in post-chemotherapeutic cancer survivors.
Save time & money - Smart Internet Solutions      Why do you need a reservation system?